Kategória: Výskum

Spoločnosť SOM Biotech ukončila nábor do štúdie fázy IIb liečby chorey pri Huntingtonovej chorobe

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical […]

Spoločnosť Prilenia plánuje predložiť žiadosť o registráciu pridopidínu pri Huntingtonovej chorobe v EÚ

Prilenia announced today that they plan to submit a Marketing Authorization Application in the EU for the use of Pridopidine in the treatment of Huntington’s Disease. According to Dr. Michael […]

Prelomový objav predstavuje novú nádej pre pacientov s HD

Scientists from the Weizmann Institute in Israel have published the results of an animal study which holds tremendous promise for the treatment of Huntington’s Disease.  They have discovered that two […]

Spoločnosť uniQure oznamuje aktualizáciu klinických skúšok fázy I/II génovej terapie AMT-130 na liečbu Huntingtonovej choroby

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean […]

Spoločnosť PTC Therapeutics zdieľa pozitívne priebežné údaje z klinickej štúdie PIVOT-HD u pacientov s Huntingtonovou chorobou

June 21, 2023 PDF Version – Dose-dependent lowering of blood Huntingtin (HTT) protein levels at 12 weeks –– Favorable tolerability profile with no treatment-related serious adverse events or NfL spikes –  – Conference […]

Spoločnosť uniQure oznamuje aktualizáciu americkej fázy I/II klinického skúšania génovej terapie AMT-130 na liečbu Huntingtonovej choroby

~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural history […]

PRILENIA OZNÁMILA VÝSLEDKY ŠTÚDIE PROOF-HD: SĽUBNÉ, ALE ZMIEŠANÉ VÝSLEDKY!

Today, April 25th, Prilenia announced results from the PROOF-HD clinical trial for Huntington’s Disease. Some of the participants showed significant benefits from the Pridopidine drug, while others did not benefit at all.  This […]

Prilenia dosiahla poslednú návštevu pacienta v 3. fáze klinickej štúdie PROOF-HD pre Huntingtonovu chorobu

PROOF-HD is the only late-stage study in Huntington’s disease targeting clinical progression; topline results expected in early Q2 2023 NAARDEN, Netherlands and WALTHAM, Mass., 28 March 2023 – Prilenia Therapeutics B.V., a […]

Aktuálne informácie spoločnosti Roche/Genentech o štúdii GENERATION HD2

Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, […]

Spoločnosť Novartis ukončuje štúdiu VIBRANT-HD

Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news […]